A detailed history of Commodore Capital LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Commodore Capital LP holds 1,425,000 shares of CLDX stock, worth $62.9 Million. This represents 4.73% of its overall portfolio holdings.

Number of Shares
1,425,000
Previous 866,468 64.46%
Holding current value
$62.9 Million
Previous $36.4 Million 45.03%
% of portfolio
4.73%
Previous 3.14%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$32.76 - $42.56 $18.3 Million - $23.8 Million
558,532 Added 64.46%
1,425,000 $52.7 Million
Q1 2024

May 15, 2024

BUY
$35.22 - $51.88 $5.79 Million - $8.53 Million
164,501 Added 23.43%
866,468 $36.4 Million
Q4 2023

Feb 14, 2024

SELL
$22.61 - $40.65 $106,221 - $190,973
-4,698 Reduced 0.66%
701,967 $27.8 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $1.91 Million - $2.81 Million
75,000 Added 11.87%
706,665 $19.4 Million
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $4.11 Million - $5.2 Million
135,842 Added 27.4%
631,665 $21.4 Million
Q4 2022

Feb 14, 2023

SELL
$27.78 - $45.38 $1.19 Million - $1.95 Million
-42,989 Reduced 7.98%
495,823 $22.1 Million
Q2 2022

Aug 15, 2022

BUY
$20.5 - $37.33 $6.1 Million - $11.1 Million
297,613 Added 123.39%
538,812 $14.5 Million
Q1 2022

May 16, 2022

BUY
$27.64 - $39.32 $6.67 Million - $9.48 Million
241,199 New
241,199 $8.22 Million
Q4 2021

Feb 14, 2022

SELL
$35.68 - $56.27 $8.86 Million - $14 Million
-248,207 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$28.95 - $55.99 $2.18 Million - $4.21 Million
-75,230 Reduced 23.26%
248,207 $13.4 Million
Q2 2021

Aug 16, 2021

SELL
$20.71 - $35.37 $963,304 - $1.65 Million
-46,514 Reduced 12.57%
323,437 $10.8 Million
Q1 2021

May 17, 2021

BUY
$16.19 - $29.91 $218,888 - $404,383
13,520 Added 3.79%
369,951 $7.62 Million
Q4 2020

Feb 16, 2021

BUY
$14.99 - $22.75 $5.34 Million - $8.11 Million
356,431 New
356,431 $6.25 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $2.07B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Commodore Capital LP Portfolio

Follow Commodore Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.